Log in
Registerraloxifene [Design Issues]
Dear Mr John,
The literature reported Intrasubject variability of Raloxifene for Cmax was 39.59% as per the bioequivalence study submitted to EMA.
Reference: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001075/WC500091423.pdf
❝ Does anyone have experience with raloxifene? If so, what is the intrasubject cv? According to literature it's a HVD (ISCV>=30) but no exact figure.
The literature reported Intrasubject variability of Raloxifene for Cmax was 39.59% as per the bioequivalence study submitted to EMA.
Reference: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001075/WC500091423.pdf
—
Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn
Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn
Complete thread:
- raloxifene jag009 2015-07-15 16:39
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- raloxifene Mauricio Sampaio 2015-07-17 00:59
- raloxifene CV d_labes 2015-07-17 08:05
- raloxifenedrgunasakaran1 2015-07-19 16:46
- raloxifene CV jag009 2015-07-20 06:42
- raloxifene Mauricio Sampaio 2015-07-17 00:59
Ing. Helmut Schütz